Compare · HUM vs PSNL
HUM vs PSNL
Side-by-side comparison of Humana Inc. (HUM) and Personalis Inc. (PSNL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and PSNL operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $43.76B, about 43.5x PSNL ($1.01B).
- Over the past year, HUM is up 57.1% and PSNL is up 64.1% - PSNL leads by 7.0 points.
- PSNL has been more active in the news (11 items in the past 4 weeks vs 5 for HUM).
- HUM has more recent analyst coverage (25 ratings vs 14 for PSNL).
- Company
- Humana Inc.
- Personalis Inc.
- Price
- $364.43+0.36%
- $9.60-1.59%
- Market cap
- $43.76B
- $1.01B
- 1M return
- +32.89%
- +65.52%
- 1Y return
- +57.14%
- +64.10%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 5
- 11
- Recent ratings
- 25
- 14
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Personalis Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.
Latest HUM
- Humana Announces Agreement to Divest Minority Interest in Gentiva
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
- Humana upgraded by Deutsche Bank with a new price target
- Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Humana, CenterWell and USAA Unite with VFW for National Day of Service Supporting Veterans Experiencing Homelessness
- Humana Invests More Than $1 Million to Advance Health Outcomes Across Louisiana
- Chief Financial Officer Mellet Celeste gave a grant of 15,387 units of Humana Common, decreasing direct ownership by 28% to 39,637 units (SEC Form 4)
- Chief Information Officer Mehta Japan was granted 9,448 units of Humana Common, increasing direct ownership by 122% to 17,176 units (SEC Form 4)
- President, Enterprise Growth Dintenfass David was granted 11,273 units of Humana Common, increasing direct ownership by 80% to 25,407 units (SEC Form 4)
Latest PSNL
- Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
- CFO AND COO Tachibana Aaron exercised 40,000 shares at a strike of $9.16 and sold $480,400 worth of shares (40,000 units at $12.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
- Chief Executive Officer Hall Christopher M sold $1,102,000 worth of shares (100,000 units at $11.02) as part of a pre-agreed trading plan and exercised 100,000 shares at a strike of $1.61 (SEC Form 4)
- CFO AND COO Tachibana Aaron sold $449,292 worth of shares (38,799 units at $11.58) as part of a pre-agreed trading plan and exercised 38,799 shares at a strike of $9.16 (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- SEC Form 144 filed by Personalis Inc.
- Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
- Personalis Inc. filed SEC Form 8-K: Other Events